The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Lipid–Drug Conjugate for Enhancing Drug Delivery
Open accessAbstract
Lipid-drug conjugates (LDCs) are drug molecules that have been covalently modified with lipids. The conjugation of lipids to drug molecules increases lipophilicity and also changes other properties of drugs. The conjugates demonstrate several advantages including improved oral bioavailability, improved targeting to the lymphatic system, enhanced tumor targeting, and reduced toxicity. Based on the chemical nature of drugs and lipids, various conjugation strategies and chemical linkers can be utilized to synthesize LDCs. Linkers and/or conjugation methods determine how drugs are released from LDCs and are critical for the optimal performance of LDCs. In this review, different lipids used for preparing LDCs and various conjugation strategies are summarized. Although LDCs can be administered without a delivery carrier, most of them are loaded into appropriate delivery systems. The lipid moiety in the conjugates can significantly enhance drug loading into hydrophobic components of delivery carriers and thus generate formulations with high drug loading and superior stability. Different delivery carriers such as emulsions, liposomes, micelles, lipid nanoparticles, and polymer nanoparticles are also discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011379108 · Cited by 513
Squalenoyl Nanomedicines as Potential Therapeutics
Couvreur, P., Stella, B., Reddy, L. H., Hillaireau, H., Dubernet, C., Desmaële, D., Lepêtre-Mouelhi, S., Rocco, F., Dereuddre-Bosquet, N., Clayette, P., et al. (2006) · Nano Letters · doi:10.1021/nl061942q · Cited by 329
Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol
Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H., & Yokota, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.14 · Cited by 312
Maksimenko, A., Dosio, F., Mougin, J., Ferrero, A., Wack, S., Reddy, L. H., Weyn, A.-A., Lepeltier, E., Bourgaux, C., Stella, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313459110 · Cited by 212
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley, M. O., Webb, N. L., Anthony, F. H., Devanesan, P. D., Witman, P. A., Hemamalini, S., Chander, M. C., Baker, S. D., He, L., Horwitz, S. B., et al. (2001) · PubMed · Cited by 180
Wang, J.-X., Sun, X., & Zhang, Z.-R. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00083-8 · Cited by 179
Olbrich, C., Gessner, A., Kayser, O., & Müller, R. H. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000001832 · Cited by 175
Nikanjam, M., Gibbs, A. R., Hunt, C. A., Budinger, T. F., & Forte, T. M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.09.007 · Cited by 165
Arias, J. L., Reddy, L. H., Othman, M., Gillet, B., Desmaële, D., Zouhiri, F., Dosio, F., Gref, R., & Couvreur, P. (2011) · ACS Nano · doi:10.1021/nn1034197 · Cited by 163
Hyaluronic acid-coated liposomes for active targeting of gemcitabine
Arpicco, S., Lerda, C., Dalla Pozza, E., Costanzo, C., Tsapis, N., Stella, B., Donadelli, M., Dando, I., Fattal, E., Cattel, L., et al. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.06.003 · Cited by 159
A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration
Lundberg, B., Risovic, V., Ramaswamy, M., & Wasan, K. M. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00323-1 · Cited by 144
Reddy, L. H., Dubernet, C., Lepêtre‐Mouelhi, S., Marque, P. E., Desmaële, D., & Couvreur, P. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.018 · Cited by 143
A Folate Receptor?Targeted Lipid Nanoparticle Formulation for a Lipophilic Paclitaxel Prodrug
Stevens, P. J., Sekido, M., & Lee, R. J. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7667-5 · Cited by 140
Rationale and applications of lipids as prodrug carriers
Lambert, D. M. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00161-5 · Cited by 139
Karra, N., Nassar, T., Ripin, A. N., Schwob, O., Borlak, J. T., & Benita, S. (2013) · Small · doi:10.1002/smll.201301417 · Cited by 136
Couvreur, P., Reddy, L. H., Mangenot, S., Poupaert, J. H., Desmaële, D., Lepêtre‐Mouelhi, S., Pili, B., Bourgaux, C., Amenitsch, H. W., & Ollivon, M. (2008) · Small · doi:10.1002/smll.200700731 · Cited by 131
Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma
Bastiancich, C., Vanvarenberg, K., Učakar, B., Pitorre, M., Bastiat, G., Lagarce, F., Véronique Préat, A., & Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.054 · Cited by 129
Ansell, S. M., Johnstone, S. A., Tardi, P. G., Lo, L., Xie, S., Shu, Y., Harasym, T. O., Harasym, N. L., Williams, L. A., Bermudes, D. G., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800002y · Cited by 126
Rodrigues, D. G., Maria, D. A., Fernandes, D. C., Valduga, C. J., Couto, R. D., Ibañez, O. M., & Maranhão, R. C. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0930-y · Cited by 121
Onishchenko, N. R., Sevrin, C., Lespineux, D., Bovin, N. V., Vodovozova, E. L., Mészáros, T., Szebeni, J., & Grandfils, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.010 · Cited by 118
Forrest, M. L., Yáñez, J. A., Remsberg, C. M., Ohgami, Y., Kwon, G. S., & Davies, N. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9451-9 · Cited by 115
Raouane, M., Desmaële, D., Gilbert-Sirieix, M., Gueutin, C., Zouhiri, F., Bourgaux, C., Lepeltier, É., Gref, R., Salah, R. B., Clayman, G. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000272 · Cited by 111
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles
Sloat, B. R., Sandoval, M. A., Li, D., Chung, W.-G., Lansakara-P, D. S. P., Proteau, P., Kiguchi, K., DiGiovanni, J., & Cui, Z. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.037 · Cited by 104
Réjiba, S., Reddy, L. H., Bigand, C., Parmentier, C., Couvreur, P., & Hajri, A. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.02.012 · Cited by 103
Shao, W., Paul, A., Zhao, B., Lee, C., Rodes, L., & Prakash, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.007 · Cited by 102
Tumor targeting by conjugation of DHA to paclitaxel
Bradley, M. O., Swindell, C. S., Anthony, F. H., Witman, P. A., Devanesan, P. D., Webb, N. L., Baker, S. D., Wolff, A. C., & Donehower, R. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00321-2 · Cited by 101
Han, S., Quach, T., Hu, L., Wahab, A., Charman, W. N., Stella, V. J., Trevaskis, N. L., Simpson, J. S., & Porter, C. J. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.12.031 · Cited by 100
Duhem, N., Danhier, F., Pourcelle, V., Schumers, J., Bertrand, O., Duff, C. S. L., Hoeppener, S., Schubert, U. S., Gohy, J., Marchand‐Brynaert, J., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400326y · Cited by 97
Petrova, N. S., Chernikov, I. V., Meschaninova, M. I., Dovydenko, I. S., Venyaminova, A. G., Аркадьевна, З. М., Vlassov, V. V., & Chernolovskaya, E. L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1002 · Cited by 97
Reddy, L. H., Khoury, H., Paci, A., Deroussent, A., Ferreira, H. J., Dubernet, C., Declèves, X., Besnard, M., Chacun, H., Lepêtre‐Mouelhi, S., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020735 · Cited by 97
Gabizon, A., Tzemach, D., Horowitz, A. T., Shmeeda, H., Yeh, J., & Zalipsky, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1547 · Cited by 97
Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals
Gollnest, T., de Oliveira, T. D., Schols, D., Balzarini, J. M., & Meier, C. (2015) · Nature Communications · doi:10.1038/ncomms9716 · Cited by 93
Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery
Zaro, J. L. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9670-z · Cited by 93
Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics
Remenar, J. F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500070m · Cited by 92
Synthesis and Biophysical Characterization of Chlorambucil Anticancer Ether Lipid Prodrugs
Pedersen, P. J., Christensen, M. S., Ruysschaert, T., Linderoth, L., Andresen, T. L., Melander, F., Mouritsen, O. G., Madsen, R., & Clausen, M. H. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900091h · Cited by 91
Dosio, F., Reddy, L. H., Ferrero, A., Stella, B., Cattel, L., & Couvreur, P. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100154g · Cited by 90
Zhu, S., Lansakara-P, D. S. P., Li, X., & Cui, Z. (2012) · Bioconjugate Chemistry · doi:10.1021/bc2005945 · Cited by 85
Targeting cancer using cholesterol conjugates
Radwan, A. A., & Alanazi, F. K. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.01.003 · Cited by 84
Sagnella, S. M., Gong, X., Moghaddam, M. J., Conn, C. E., Kimpton, K., Waddington, L. J., Krodkiewska, I., & Drummond, C. J. (2010) · Nanoscale · doi:10.1039/c0nr00781a · Cited by 84
Dalpiaz, A., Paganetto, G., Pavan, B., Fogagnolo, M., Medici, A., Beggiato, S., & Perrone, D. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200565g · Cited by 81
Pires, L. A., Hegg, R., Valduga, C. J., Graziani, S. R., Rodrigues, D. G., & Maranhão, R. C. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0738-2 · Cited by 79
Zalipsky, S., Saad, M., Kiwan, R., Ber, E., Yu, N. Y., & Minko, T. (2007) · Journal of drug targeting · doi:10.1080/10611860701499946 · Cited by 77
Maksimenko, A., Alami, M., Zouhiri, F., Brion, J., Pruvost, A., Mougin, J., Hamzé, A., Boissenot, T., Provot, O., Desmaële, D., et al. (2014) · ACS Nano · doi:10.1021/nn500517a · Cited by 77
Enhanced Tumor Delivery of Gemcitabine via PEG-DSPE/TPGS Mixed Micelles
Wang, Y., Fan, W. Q., Dai, X., Katragadda, U., Mckinley, D., Teng, Q., & Tan, C. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4005904 · Cited by 75
Reddy, L. H., Renoir, J., Marsaud, V., Lepêtre‐Mouelhi, S., Desmaële, D., & Couvreur, P. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900099e · Cited by 74
Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy
Bala, V., Rao, S., Li, P., Wang, S., & Prestidge, C. A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00785 · Cited by 73
Hu, L., Quach, T., Han, S., Lim, S. F., Yadav, P., Senyschyn, D., Trevaskis, N. L., Simpson, J. S., & Porter, C. J. H. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604207 · Cited by 73
Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
Nishina, T., Numata, J., Nishina, K., Yoshida‐Tanaka, K., Nitta, K., Piao, W., Iwata, R., Ito, S., Kuwahara, H., Wada, T., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.72 · Cited by 72
Caron, J., Maksimenko, A., Wack, S., Lepeltier, É., Bourgaux, C., Morvan, E., Leblanc, K., Couvreur, P., & Desmaële, D. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200099 · Cited by 72
Weber, R. J., Liang, S. I., Selden, N. S., Desai, T. A., & Gartner, Z. J. (2014) · Biomacromolecules · doi:10.1021/bm501467h · Cited by 70
Antitumoral Activity of Liposomes and Immunoliposomes Containing 5-Fluorouridine Prodrugs
Crosasso, P., Brusa, P., Dosio, F., Arpicco, S., Pacchioni, D., Schuberî, F., & Cattel, L. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9604467 · Cited by 70
Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds
Perkins, W. R., Ahmad, I. N., Li, X., Hirsh, D. J., Masters, G. R., Fecko, C. J., Lee, J., Ali, S., Nguyen, J., Schupsky, J. J., et al. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00329-x · Cited by 70
Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery
Chen, Q., Butler, D., Querbes, W., Pandey, R. K., Ge, P., Maier, M. A., Zhang, L., Rajeev, K. G., Nechev, L. V., Koteliansky, V., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.011 · Cited by 69
Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy
Bui, D. T., Nicolas, J., Maksimenko, A., Desmaële, D., & Couvreur, P. (2013) · Chemical Communications · doi:10.1039/c3cc47427e · Cited by 69
Chung, W.-G., Sandoval, M. A., Sloat, B. R., Lansakara-P, D. S. P., & Cui, Z. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.004 · Cited by 68
Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor
Valetti, S., Maione, F., Mura, S., Stella, B., Desmaële, D., Noiray, M., Vergnaud, J., Vauthier, C., Cattel, L., Giraudo, E., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.039 · Cited by 67
Effenberger, K. E., Breyer, S., & Schobert, R. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.01.037 · Cited by 67
A review of paliperidone palmitate
Chue, P. S., & Chue, J. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.137 · Cited by 66
EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity
Sandoval, M. A., Sloat, B. R., Lansakara-P, D. S. P., Kumar, A., Rodriguez, B. L., Kiguchi, K., DiGiovanni, J., & Cui, Z. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.015 · Cited by 66
Gabizón, A., Amitay, Y., Tzemach, D., Gorin, J., Shmeeda, H., & Zalipsky, S. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.019 · Cited by 66
Daman, Z., Ostad, S. N., Amini, M., & Gilani, K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.04.021 · Cited by 65
Lipases, liposomes and lipid-prodrugs
Arouri, A., Hansen, A. H., Rasmussen, T. E., & Mouritsen, O. G. (2013) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2013.06.001 · Cited by 65
A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms
Alexander, R. L., Greene, B. T., Torti, S. V., & Kucera, G. L. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0949-0 · Cited by 65
Zhu, S., Wonganan, P., Lansakara-P, D. S. P., O’Mary, H. L., Li, Y., & Cui, Z. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.053 · Cited by 63
Cheng, K., Ye, Z., Guntaka, R. V., & Mahato, R. I. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100347 · Cited by 63
Prodrug Strategy for PSMA-Targeted Delivery of TGX-221 to Prostate Cancer Cells
Zhao, Y., Duan, S., Zeng, X., Liu, C., Davies, N. M., Li, B., & Forrest, M. L. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3000309 · Cited by 61
Pan, D., Schmieder, A. H., Wang, K., Yang, X., Senpan, A., Cui, G., Killgore, K., Kim, B. B., Allen, J. S., Zhang, H., et al. (2014) · Theranostics · doi:10.7150/thno.7581 · Cited by 59
Sun, B., Luo, C., Li, L., Wang, M., Du, Y., Di, D., Zhang, D., Ren, G., Pan, X., Fu, Q., et al. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.02.065 · Cited by 57
Xiong, M. P., Yáñez, J. A., Remsberg, C. M., Ohgami, Y., Kwon, G. S., Davies, N. M., & Forrest, M. L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.015 · Cited by 54
Novel Isoprenoyl Nanoassembled Prodrug for Paclitaxel Delivery
Mura, S., Zouhiri, F., Lerondel, S., Maksimenko, A., Mougin, J., Gueutin, C., Brambilla, D., Caron, J., Śliwiński, É., Pape, A. L., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400210x · Cited by 51
Daull, P., Paterson, C. A., Kuppermann, B. D., & Garrigue, J. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0044 · Cited by 48
Lansakara-P, D. S. P., Rodriguez, B. L., & Cui, Z. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.014 · Cited by 48
Wonganan, P., Lansakara-P, D. S. P., Zhu, S., Holzer, M., Sandoval, M. A., Warthaka, M., & Cui, Z. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.033 · Cited by 47
Yu, B., Sun, X., & Zhang, Z. (2003) · Archives of Pharmacal Research · doi:10.1007/bf02994764 · Cited by 47
Borrelli, S., Christodoulou, M. S., Ficarra, I., Silvani, A., Cappelletti, G., Cartelli, D., Damia, G. L. M., Ricci, F., Zucchetti, M., Dosio, F., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.035 · Cited by 45
Neutsch, L., Wirth, E.-M., Spijker, S., Pichl, C., Kählig, H., Gabor, F., & Wirth, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.004 · Cited by 44
Borkar, N., Li, B., Holm, R., Håkansson, A. E., Müllertz, A., Yang, M., & Mu, H. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.014 · Cited by 43
Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy
Alferiev, I. S., Iyer, R., Courtland, J. L., Adamo, R. F., Zhang, K., Mangino, J. L., Kolla, V., Fishbein, I., Brodeur, G. M., Levy, R. J., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.075 · Cited by 43
Enhancement of docetaxel solubility via conjugation of formulation-compatible moieties
Huynh, L., Leroux, J., & Allen, C. J. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b906862g · Cited by 43
Gong, X., Moghaddam, M. J., Sagnella, S. M., Conn, C. E., Danon, S. J., Waddington, L. J., & Drummond, C. J. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.03.007 · Cited by 42
Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation
Pili, B., Reddy, L. H., Bourgaux, C., Lepêtre‐Mouelhi, S., Desmaële, D., & Couvreur, P. (2010) · Nanoscale · doi:10.1039/c0nr00132e · Cited by 42
Han, S., Hu, L., Gracia, Quach, T., Simpson, J. S., Edwards, G. A., Trevaskis, N. L., & Porter, C. J. H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00195 · Cited by 42
Han, S., Hu, L., Quach, T., Simpson, J. S., Trevaskis, N. L., & Porter, C. J. H. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1579-9 · Cited by 41
Peptide Conjugation: Before or After Nanoparticle Formation?
Valetti, S., Mura, S., Noiray, M., Arpicco, S., Dosio, F., Vergnaud, J., Desmaële, D., Stella, B., & Couvreur, P. (2014) · Bioconjugate Chemistry · doi:10.1021/bc5003423 · Cited by 40
Ali, H. M., Maksimenko, A., Urbinati, G., Chapuis, H., Raouane, M., Desmaële, D., Hayashi, Y., Harashima, H., Couvreur, P., & Massaad-Massade, L. (2013) · Thyroid · doi:10.1089/thy.2012.0544 · Cited by 39
Amitay, Y., Shmeeda, H., Patil, Y. P., Gorin, J., Tzemach, D., Mak, L., Ohana, P., & Gabizón, A. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1819-7 · Cited by 37
Zhang, X., Du, R., Zhong, T., Zhang, W.-Q., Song, P., Song, W.-D., Zhao, Y., Wang, C., Tang, Y., & Zhang, Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s65664 · Cited by 36
Sarett, S. M., Kilchrist, K. V., Miteva, M., & Duvall, C. L. (2015) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35413 · Cited by 32
Anticancer double lipid prodrugs: liposomal preparation and characterization
Arouri, A., & Mouritsen, O. G. (2011) · Journal of Liposome Research · doi:10.3109/08982104.2011.563365 · Cited by 32
Lundberg, B. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.061 · Cited by 28
Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide
Urbinati, G., de Waziers, I., Slamić, M., Foussignière, T., Ali, H. M., Desmaële, D., Couvreur, P., & Massaad-Massade, L. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.16 · Cited by 28
Dalpiaz, A., Contado, C., Mari, L., Perrone, D., Pavan, B., Paganetto, G., Hanuskovà, M., Vighi, E., & Leo, E. (2013) · Drug Delivery · doi:10.3109/10717544.2013.844744 · Cited by 27
Cheikh‐Ali, Z., Caron, J., Cojean, S., Bories, C., Couvreur, P., Loiseau, P. M., Desmaële, D., Poupon, E., & Champy, P. (2014) · ChemMedChem · doi:10.1002/cmdc.201402449 · Cited by 27
Peng, L., Feng, L., Yuan, H., Benhabbour, S. R., & Mumper, R. J. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.03.016 · Cited by 27
Stella, B., Arpicco, S., Rocco, F., Burgalassi, S., Nicosia, N., Tampucci, S., Chetoni, P., & Cattel, L. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.10.001 · Cited by 26
Ajaj, K. A., Graeser, R., & Kratz, F. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1937-9 · Cited by 25
Jin, Y., Lian, Y., & Du, L. (2011) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2011.11.001 · Cited by 25
Peira, E., Chirio, D., Battaglia, L., Barge, A., Chegaev, K. Y., Gigliotti, C. L., Ferrara, B., Dianzani, C., & Gallarate, M. (2016) · Journal of Microencapsulation · doi:10.1080/02652048.2016.1202342 · Cited by 25
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Li, F., Snow-Davis, C., Du, C., Bondarev, M. L., Saulsbury, M. D., & Heyliger, S. O. (2016) · Journal of Visualized Experiments · doi:10.3791/54338 · Cited by 24
Self-citationA nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity
Zhu, S., Li, X., Lansakara-P, D. S. P., et al. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01599.x · Cited by 22
Yadav, K., Bhargava, P., Bansal, S., Singh, M. P., Gupta, S., Sandhu, G., Kumar, S., Sreekanth, V., & Bajaj, A. (2015) · MedChemComm · doi:10.1039/c4md00289j · Cited by 20
Lepeltier, É., Bourgaux, C., Amenitsch, H. W., Rosilio, V., Lepêtre‐Mouelhi, S., Zouhiri, F., Desmaële, D., & Couvreur, P. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.07.004 · Cited by 17
Lipophilic nalmefene prodrugs to achieve a one-month sustained release
Gaekens, T., Guillaume, M., Borghys, H., de Zwart, L. L., de Vries, R., Embrechts, R. C. A., Vermeulen, A., Megens, A. A. H. P., Leysen, J. E., Herdewijn, P. A., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.029 · Cited by 15
Synthesis of a fluorescent analogue of methotrexate lipophilic prodrug
Vlasenko, Y. V., Alekseeva, A. S., & Vodovozova, E. L. (2014) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162014010129 · Cited by 3
Cited by
Liu, P., Chen, G., & Zhang, J. (2022) · Molecules · doi:10.3390/molecules27041372 · Cited by 1,334
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114097 · Cited by 424
Immunological and Toxicological Considerations for the Design of Liposomes
Inglut, C. T., Sorrin, A. J., Kuruppu, T., Vig, S., Cicalo, J., Ahmad, H., & Huang, H.-C. (2020) · Nanomaterials · doi:10.3390/nano10020190 · Cited by 371
Duong, V.-A., Nguyen, T.-T.-L., & Maeng, H.-J. (2020) · Molecules · doi:10.3390/molecules25204781 · Cited by 338
Metadata
- Authors
- Irby, D., Du, C., & Li, F.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-01-24
- Volume
- 14
- Issue
- 5
- Pages
- 1325-1338
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2574256996
- Cited by
- 331
- References
- 107
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.